What more is there to learn about trachoma? | British Journal of Ophthalmology

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via AAO

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Responses

Editorial

What more is there to learn about trachoma?

Free

Compose a Response to This Article

Compose Response

Title *

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

No

Please describe the competing interests

PLEASE NOTE:

A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.

I agree to and have read the terms and conditions for rapid responses and BMJ Privacy Notice *

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

Trachoma: Time to learn from what is known
Hannah Kuper
Published on: 21 May 2003

Published on: 21 May 2003
Trachoma: Time to learn from what is known
- Hannah Kuper, Lecturer
- Other Contributors:
  John C Buchan, Allen Foster
Dear Editor
We read with interest the recent editorial entitled "What more is there to learn about trachoma" by Melese et al.[1] Trachoma is responsible for up to 6 million cases of blindness worldwide, yet to a large extent it is a forgotten disease which affects the poorest and most medically underserved people.
The World Health Organisation (WHO) together with the International Agency for Preven...
Show More

Dear Editor
We read with interest the recent editorial entitled "What more is there to learn about trachoma" by Melese et al.[1] Trachoma is responsible for up to 6 million cases of blindness worldwide, yet to a large extent it is a forgotten disease which affects the poorest and most medically underserved people.
The World Health Organisation (WHO) together with the International Agency for Prevention of Blindness jointly launched "VISION 2020 – the right to sight" in 1999 which aims to eliminate avoidable blindness by the year 2020, including blindness from trachoma. WHO has endorsed "SAFE" (Surgery for trichiasis, Antibiotics to reduce the prevalence of chlamydial infection, and Facial cleanliness and Environmental change to reduce the disease transmission) as the strategy implemented by national programmes to achieve the elimination of blinding trachoma. We have recently undertaken a review of the evidence base of the SAFE strategy and judged it to be strong for the surgery and antibiotics components, but weaker for the other components.[2] We therefore concur with the opinion of Melese et al. that more research is required, not only to develop a protocol for the rational use of antibiotics, as they suggest, but also to strengthen the evidence relating to the ‘F’ and ‘E’ components.
The SAFE strategy has been implemented by the national trachoma control programmes of many endemic countries in Africa, Asia and Latin America with varying degrees of success. Melese et al make the observation that the experiences gained from research studies are not directly transferable to real life settings; the need, therefore, is for the publication of the experiences of countries that have successfully dealt with trachoma through implementation of the SAFE strategy to serve as a best practice model for other countries. Morocco is a good example. A decade ago trachoma was a public health problem in five provinces of Morocco, but with the efficient implementation of the SAFE strategy the prevalence of active trachoma and trichiasis have declined dramatically so that Morocco is now close to eliminating trachoma as a public health problem.[3] Real life country examples such as Morocco documented as case studies allow policy makers and programme managers to learn from the mistakes and successes of public health programmes, because, as Melese et al. point out, real life is messier and more complicated than research studies.
References
(1) Melese M, Alemayehu W, Gaynor B, Yi E, Whitcher JP, Lietman TM. What more is there to learn about trachoma? Br J Ophthalmol 2003;87:521- 522.
(2) Kuper H, Solomon AW, Buchan J, Zondervan M, Foster A, Mabey D. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis, in press.
(3) Ferriman A. Blinding trachoma almost eliminated from Morocco. BMJ 2001;323;1387.
Show Less

Conflict of Interest:
None declared.
- Back to top